跳至主要内容
临床试验/NCT03910634
NCT03910634Unknown2 期

IMRT Combined With Carboplatin Versus IMRT Combined With Carboplatin and Fluorouracil in the Treatment of Locally Advanced Esophageal Cancer in Elderly Patients With High Risk of Chemotherapy: a Randomized Controlled Clinical Study

Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 264 人开始时间: 2019年4月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
264
试验地点
1
主要终点
Overall objective response rate

研究概览

简要总结

An open, single-center, randomized controlled phase II clinical trial to compare the efficacy and safety of conformal intensity modulated radiation therapy (IMRT) combined with carboplatin and IMRT combined with carboplatin and 5-FU in elderly patients with locally advanced esophageal squamous cell carcinoma at high risk of chemotherapy

详细描述

Esophageal cancer is one of the most common malignant tumors in China.To compare the efficacy and safety of conformal intensity modulated radiation therapy (IMRT) combined with carboplatin and IMRT combined with carboplatin and 5-FU in elderly patients with locally advanced esophageal squamous cell carcinoma at high risk of chemotherapy.This trial is an open, single-center, randomized controlled phase II clinical trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
65 Years 至 85 Years(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age (> 65 years)
  • Histologically confirmed esophageal squamous cell carcinoma, the 8th edition of AJCC stage T3-4NxM0 or TxN1-3M0, without surgical indications after consultation by surgeons.
  • PS score < 2, Chemotherapy risk score is medium and high risk
  • No radical thoracic surgery/chemotherapy/radiotherapy/targeted therapy has been performed in the past.
  • Diseases measurable according to RECIST standards
  • Hematological examination requires Hb (>90g/L), ANC (>2.0 *109/L) and platelet (>100 *109/L). Serum albumin (>3.0g/dL)
  • Serum creatinine < 1.25 times normal upper limit (UNL), or creatinine clearance rate (>60 ml/min). Total bilirubin < upper limit of normal value
  • Total bilirubin < the upper limit of normal value, AST (SGOT) and ALT (SGPT) < 2.5 times the upper limit of normal value, ALP < 2.5 times the upper limit of normal value (ULN)
  • If exploratory surgery is performed, the patient will recover at least 2 weeks after operation.

排除标准

  • Pregnant or lactating women.
  • Patients with fertility without adequate contraceptive measures.
  • Anaphylaxis to 5FU and carboplatin is known.
  • Anaphylaxis known to exist with any drug in the study
  • Other malignant tumors have occurred in the past five years, except cervical carcinoma in situ or non-melanoma skin cancer, which has been properly treated.
  • Discovery of esophageal fistula or risk of esophageal bleeding before treatment
  • Distant organ metastasis is known
  • Symptomatic peripheral neuropathy, according to NCIC-CTC criteria (> grade 2).
  • Other serious diseases or medical conditions: Myocardial infarction (in the past six months), severe unstable angina pectoris and congestive heart failure have occurred.
  • Severe complications (including intestinal paralysis, intestinal obstruction, interstitial pneumonia, pulmonary fibrosis, severe respiratory dysfunction of COPD, cardiac dysfunction of pulmonary heart disease, uncontrolled diabetes mellitus, renal insufficiency and cirrhosis of liver, etc.)
  • Gastrointestinal bleeding requires frequent blood transfusion.
  • It is known to carry human immunodeficiency virus (HIV) or AIDS.
  • Suffering from mental illness
  • The known neuropathy is of grade 2 or higher severity.

研究组 & 干预措施

IMRT combined with carboplatin

Experimental

Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks

干预措施: Intensity modulated radiation therapy (Radiation)

IMRT combined with carboplatin

Experimental

Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks

干预措施: carboplatin (Drug)

IMRT combined with carboplatin and fluorouracil

Placebo Comparator

Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks

干预措施: Fluorouracil (Drug)

IMRT combined with carboplatin and fluorouracil

Placebo Comparator

Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks

干预措施: Intensity modulated radiation therapy (Radiation)

IMRT combined with carboplatin and fluorouracil

Placebo Comparator

Intensity modulated radiation therapy 50-60Gy, Carboplatin (AUC 2), QW1, intravenous drip; Fluorouracil 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks

干预措施: carboplatin (Drug)

结局指标

主要结局

Overall objective response rate

时间窗: up to 24 months

The proportion of partial and complete remission of tumors

次要结局

  • Incidence of toxic and side effects above 3 degrees(up to 24 months)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhu Yujia

Doctor

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验